Arrowhead Pharmaceuticals, Inc. ARWR
47.78 USD +0.63 (+1.34%)
Regular-session close
46.90 -0.88 -1.84%
After hours · Nov 13, 4:00 PM ET
44.52 Day range 48.29
37.06 52-week range 95.49
- YTD
- -28.03%
- 1 year
- +16.14%
News
defenseworld.net 94,000 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR Bought by ACT Capital Partners L.P. ACT Capital Partners L.P. acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) in the third quarter, according to its most recent 13F filing with the Securities and…benzinga.com RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.
benzinga.com Stifel Maintains Buy on Arrowhead Pharma, Lowers Price Target to $96 Stifel analyst James Condulis maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price target from $104 to $96.
seekingalpha.com Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript
marketbeat.com Arrowhead Pharmaceuticals Q4 Earnings Call Highlights Arrowhead Pharmaceuticals NASDAQ: ARWR is preparing for a potential U.S. launch of its drug REDEMPLO in a larger patient population in the second quarter of 2027, as the company works to turn growing…benzinga.com Arrowhead Pharma Q4 EPS $(3.01) Misses $(1.61) Estimate, Sales $37.794M Miss $55.838M Estimate Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(3.01) per share which missed the analyst consensus estimate of $(1.61) by 86.96 percent. This is a 1572.22 percent decrease over losses…
businesswire.com Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting…
benzinga.com Cisco Systems, Applied Materials On Deck Thursday As AI Demand Faces Test Cisco Systems and Applied Materials headline Thursday’s reports, with investors looking for evidence that AI infrastructure demand can keep supporting semiconductor and networking growth. Brookfield,…
businesswire.com Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026…
benzinga.com Nasdaq 100 Jumps 3% as Chips Rebound; Nvidia Lags Most Since DeepSeek: Stock Market Today Wall Street rebounds from last week's rout as SOXX jumps 7%, while Nvidia slides on a CEO probe for its worst day versus the S&P 500 since DeepSeek.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.benzinga.com Reported Saturday, Arrowhead Presents Plozasiran Data At AHA 2026 Showing 78% Lower Acute Pancreatitis Event Rate Versus Placebo And Sustained Triglyceride Reductions, Plus ARO-DIMER-PA Lowering LDL Cholesterol And Triglycerides Pooled SHASTA-3 and SHASTA-4 analysis showed plozasiran reduced acute pancreatitis event rates by 78% overall and 91% in sHTG patients with a recent history of acute pancreatitis versus…
benzinga.com Arrowhead Refinances Debt, Cuts Borrowing Costs And Boosts Financial Flexibility With New $400M Sixth Street Loan - Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount- New $400 million term loan priced at SOFR plus 5.50%- Debt has no scheduled…
benzinga.com Arrowhead Pharma To Present Three-Year Data From PALISADE Study And Open-Label Extension At American Heart Association Scientific Sessions 2026 – Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking…
benzinga.com Arrowhead Pharmaceuticals’ REDEMPLO Receives UK Marketing Authorization For Familial Chylomicronaemia Syndrome; NICE Recommends NHS Funding In England And Wales For Eligible Adults With Genetically Confirmed FCS The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients…
benzinga.com Top 3 Health Care Stocks That Could Blast Off In October Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
